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Abstract Hereditaryformsofcoppertoxicosisexistinman
anddogs.Inman,Wilson’sdiseaseisthebeststudieddisorder
of copper overload, resulting from mutations in the gene
coding for the copper transporter ATP7B. Forms of copper
toxicosisforwhichnocausalgeneisknownyetarerecognized
aswell,ofteninyoungchildren.Althoughadvanceshavebeen
made in unraveling the genetic background of disorders of
coppermetabolisminman,manyquestionsregardingdisease
mechanisms and copper homeostasis remain unanswered.
Genetic studies inthe Bedlingtonterrier,a dogbreedaffected
with copper toxicosis, identiﬁed COMMD1, a gene that was
previously unknown to be involved in copper metabolism.
Besides the Bedlington terrier, a number of other dog breeds
suffer from hereditary copper toxicosis and show similar
phenotypes to humans with copper storage disorders. Unlike
the heterogeneity of most human populations, the genetic
structure within a purebred dog population is homogeneous,
which is advantageous for unraveling the molecular genetics
of complex diseases. This article reviews the work that has
been done on the Bedlington terrier, summarizes what was
learned from studies into COMMD1 function, describes
hereditary copper toxicosis phenotypes in other dog breeds,
and discusses the opportunities for genome-wide association
studies on copper toxicosis in the dog to contribute to the
understanding of mammalian copper metabolism and copper
metabolism disorders in man.
Introduction
The trace element copper plays an essential role in a
variety of biological processes, including mitochondrial
respiration, antioxidant defense, neurotransmitter synthe-
sis, connective tissue formation, pigmentation, and iron
metabolism. However, it is extremely toxic when present in
excessive amounts. Therefore, copper concentrations in the
body are tightly regulated (de Romana et al. 2011). The
importance of proper functioning of its homeostatic regu-
lation is illustrated by the genetic disorders Menkes disease
(OMIM #309400) and Wilson’s disease (OMIM #277900),
that result from mutations in genes coding for the homol-
ogous copper-transporting P-type ATPases ATP7A and
ATP7B, respectively.
Dietary copper uptake takes place in the small intestine
(Mason 1979), where CTR1 (Zhou and Gitschier 1997) and
possibly CTR2 (van den Berghe et al. 2007) and DMT1
(Gunshin et al. 1997) can facilitate copper uptake into
enterocytes. Copper is transported from the enterocytes
into the portal circulation by ATP7A that is located at the
basal membrane of the enterocyte under high copper con-
ditions (Pase et al. 2004). In the blood, copper is bound to
small molecules such as histidine and to serum proteins
like a2-macroglobulin and albumin (Moriya et al. 2008) for
transport to the liver, the primary site of copper storage
(Liu et al. 2007; McArdle et al. 1990; Weiss and Linder
1985).
Copper enters the hepatocytes via CTR1 (Kim et al.
2009) and is sequestered by small molecules like metal-
lothionein (Coyle et al. 2002) and glutathione (Freedman
et al. 1989) in the cytosol. Specialized copper chaperones
shuttle copper to their destination molecules. CCS shuttles
copper to SOD1, which participates in oxidative stress
defense (Culotta et al. 1997). COX17 is the copper
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DOI 10.1007/s00335-011-9378-7chaperone for the cytochrome C oxidase, which resides in
the mitochondrial inner membrane and plays a critical role
in the electron transport chain for cellular respiration
(Amaravadi et al. 1997).
The copper chaperone ATOX1 (Klomp et al. 1997)
delivers copper to ATP7B that is located in the trans-Golgi
compartment (Hamza et al. 1999; Larin et al. 1999; van
Dongen et al. 2004). Here, copper is necessary for the
formation of holo-ceruloplasmin, which is subsequently
secreted into the blood (Yanagimoto et al. 2011). In addi-
tion, ATP7B facilitates the excretion of excess copper into
the bile (Cater et al. 2006) (Fig. 1).
Mutations in ATP7B can result in Wilson’s disease
(WD), an autosomal recessive disorder (Bull et al. 1993;
Tanzi et al. 1993) characterized by copper accumulation in
the liver, brain, and cornea (Gitlin 2003). Clinical signs
manifest in the form of hepatic, neurologic, or psychiatric
impairment and often become evident in people in the
second or third decades of life (Merle et al. 2007)
(Table 1). The disease incidence is estimated to be 1 in
30,000 (Schilsky 1996). A wide variety of mutations in
ATP7B have been described (http://www.wilsondisease.
med.ualberta.ca/database.asp) and most patients are com-
pound heterozygotes (Kenney and Cox 2007). There is a
lack of correlation between the genotype and the pheno-
type, and individuals carrying the same mutation can show
distinct clinical signs, which poses major difﬁculties for
diagnosing the disease (Riordan and Williams 2001;
Senzolo et al. 2007). Other genes or environmental inﬂu-
ences are thought to modify clinical expression of the
disease but have not yet been identiﬁed (de Bie et al.
2007a).
Non-Wilsonian forms of hepatic copper toxicosis in man
that often occur early in childhood include Indian
Fig. 1 Model of hepatocyte copper metabolism. Copper (diamonds)
enters the cell via copper transporter 1 (CTR1) and is sequestered in
the cytoplasm by the small molecules metallothionein (MT) and
glutathione (GSH). Shuttling of copper to the destination molecules
takes place via copper chaperones. COX17 shuttles copper to the
cytochrome C oxidase (CcO) in the mitochondria. CCS is the
chaperone for superoxide dismutase (SOD1). Recently, COMMD1
was shown to interact with SOD1 and this interaction requires CCS-
mediated copper incorporation in SOD1. ATOX1 transports copper to
ATP7B in the trans-Golgi network, where incorporation of copper in
apo-ceruloplasmin (CP) takes place. Holo-ceruloplasmin is subse-
quently excreted in the plasma. The precise mechanism for export of
excess copper in the bile is not completely resolved, but it is
hypothesized that ATP7B and COMMD1 mediate fusion of copper-
loaded vesicular compartments to the apical membrane. Furthermore,
COMMD1 may play a role in the maintenance of ATP7B. XIAP can
inhibit COMMD1 by promoting its degradation, resulting in cellular
copper accumulation. XIAP itself can receive copper from CCS, and
copper binding of XIAP results in its degradation and decrease in
caspase inhibition, which may result in enhanced apoptosis
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123childhood cirrhosis (ICC) (Tanner 1998), endemic Tyro-
lean infantile cirrhosis (ETIC) (Muller et al. 1996),
and idiopathic copper toxicosis (ICT) (Scheinberg and
Sternlieb 1996) (Table 1). Although an increased incidence
can occur in certain populations, overall these diseases are
rare. Genetic defects in these forms of copper toxicosis
have not been identiﬁed yet, but consanguinity and high
dietary copper intake are reported to be involved in the
disease pathogenesis, pointing toward a genetic cause
modiﬁed by environmental factors.
Besides in man, copper storage disorders have also been
identiﬁed in other mammals, including dogs. Hereditary
canine copper toxicosis is identiﬁed with a high incidence
in a number of purebred dog populations, including
the Bedlington terrier (Hardy et al. 1975), Skye terrier
(Haywood et al. 1988), West Highland White terrier
(Thornburg et al. 1986), Dalmatian (Webb et al. 2002),
Dobermann (Mandigers et al. 2004), and Labrador retrie-
ver (Hoffmann et al. 2006). Although the disease is char-
acterized by copper accumulation in the liver leading to
inﬂammation and eventually liver cirrhosis in all breeds,
phenotypic differences in the magnitude of copper accu-
mulation, sex predisposition, and severity of the disease
exist between breeds (Table 1). One of the best studied
copperstoragedisordersindogsisBedlingtonterriercopper
toxicosis (BTCT). The identiﬁcation of the causal mutation
in COMMD1 in this breed (van De Sluis et al. 2002) was a
breakthrough in the understanding of mammalian copper
homeostasis and the use of purebred dogs to identify dis-
ease-causing genes. No mutations are currently known in
the other affected breeds, suggesting that there are more,
currently unidentiﬁed, genes involved in canine copper
homeostasis.
Recently, the purebred dog has emerged as a powerful
model to study genetic diseases because of the unique
population structure (Tsai et al. 2007). With the avail-
ability of the complete DNA sequence of the canine gen-
ome and new techniques for high-throughput genotyping
and DNA sequencing, opportunities are now open to per-
form genome-wide association studies in dogs. The high
incidence of copper storage disorders in certain dog breeds,
the resemblance with the human phenotypes, the apparent
complex etiology, and the possibility to study dietary
copper intake make copper toxicosis a promising pheno-
type for genetic studies in the dog.
Here we review the unraveling of the genetics of Bed-
lington terrier copper toxicosis and how it contributed to
the gain in knowledge of the functional aspects of COM-
MD1. Furthermore, we describe copper toxicosis pheno-
types in several dog breeds and discuss the opportunities
and possible pitfalls of genome-wide association studies in
canine copper storage disorders for the detection of new
genes underlying copper homeostasis disorders.
T
a
b
l
e
1
C
o
m
p
a
r
i
s
o
n
o
f
p
h
e
n
o
t
y
p
e
s
b
e
t
w
e
e
n
d
i
f
f
e
r
e
n
t
f
o
r
m
s
o
f
c
o
p
p
e
r
t
o
x
i
c
o
s
i
s
i
n
m
a
n
a
n
d
d
o
g
s
W
D
I
C
C
E
T
I
C
I
C
T
B
e
d
l
i
n
g
t
o
n
L
a
b
r
a
d
o
r
D
o
b
e
r
m
a
n
n
W
H
W
t
e
r
r
i
e
r
D
a
l
m
a
t
i
a
n
G
e
n
e
A
T
P
7
B
U
K
U
K
U
K
C
O
M
M
D
1
U
K
U
K
U
K
U
K
M
o
d
e
o
f
i
n
h
e
r
i
t
a
n
c
e
A
u
t
o
s
o
m
a
l
r
e
c
e
s
s
i
v
e
U
K
U
K
U
K
A
u
t
o
s
o
m
a
l
r
e
c
e
s
s
i
v
e
C
o
m
p
l
e
x
C
o
m
p
l
e
x
U
K
U
K
S
e
x
p
r
e
d
i
s
p
o
s
i
t
i
o
n
N
o
M
a
l
e
N
o
N
o
N
o
F
e
m
a
l
e
F
e
m
a
l
e
N
o
N
o
A
g
e
o
f
o
n
s
e
t
A
d
o
l
e
s
c
e
n
c
e
E
a
r
l
y
c
h
i
l
d
h
o
o
d
E
a
r
l
y
c
h
i
l
d
h
o
o
d
E
a
r
l
y
c
h
i
l
d
h
o
o
d
A
d
o
l
e
s
c
e
n
c
e
-
m
i
d
d
l
e
a
g
e
A
d
o
l
e
s
c
e
n
c
e
-
m
i
d
d
l
e
a
g
e
A
d
o
l
e
s
c
e
n
c
e
-
m
i
d
d
l
e
a
g
e
M
i
d
d
l
e
a
g
e
-
o
l
d
e
r
d
o
g
s
A
d
o
l
e
s
c
e
n
c
e
-
m
i
d
d
l
e
a
g
e
L
i
v
e
r
p
a
t
h
o
l
o
g
y
C
i
r
r
h
o
s
i
s
C
i
r
r
h
o
s
i
s
C
i
r
r
h
o
s
i
s
C
i
r
r
h
o
s
i
s
C
i
r
r
h
o
s
i
s
C
i
r
r
h
o
s
i
s
C
i
r
r
h
o
s
i
s
C
i
r
r
h
o
s
i
s
C
i
r
r
h
o
s
i
s
R
e
p
o
r
t
e
d
l
i
v
e
r
c
o
p
p
e
r
i
n
c
r
e
a
s
e
c
o
m
p
a
r
e
d
t
o
r
e
f
e
r
e
n
c
e
v
a
l
u
e
1
0
9
1
0
0
9
U
K
5
0
9
5
0
9
1
0
9
1
0
9
2
0
9
2
0
9
N
e
u
r
o
l
o
g
i
c
a
l
i
m
p
a
i
r
m
e
n
t
Y
e
s
N
o
N
o
N
o
N
o
N
o
N
o
N
o
N
o
C
e
r
u
l
o
p
l
a
s
m
i
n
D
e
c
r
e
a
s
e
d
N
o
r
m
a
l
o
r
r
a
i
s
e
d
U
K
N
o
r
m
a
l
o
r
r
a
i
s
e
d
N
o
r
m
a
l
o
r
r
a
i
s
e
d
U
K
U
K
U
K
U
K
D
i
e
t
a
r
y
i
n
ﬂ
u
e
n
c
e
M
i
n
o
r
M
a
j
o
r
M
a
j
o
r
S
u
s
p
e
c
t
e
d
M
i
n
o
r
M
a
j
o
r
U
K
U
K
U
K
U
K
u
n
k
n
o
w
n
N
o
r
m
a
l
v
a
l
u
e
s
i
n
l
i
v
e
r
c
o
p
p
e
r
f
o
r
h
u
m
a
n
s
a
r
e
\
5
0
l
g
/
g
d
w
l
a
n
d
f
o
r
d
o
g
s
\
4
0
0
l
g
/
g
d
w
l
64 H. Fieten et al.: Canine models of copper toxicosis
123Discovery of the copper toxicosis gene in the Bedlington
terrier
The appearance of a progressive form of chronic hepatitis
accompanied by high liver copper values in the Bedlington
terrier was ﬁrst described in the United States (Hardy et al.
1975). Subsequently, Bedlington terrier copper toxicosis
(BTCT) was recognized in Australia (Studdert 1982) and
Europe (Eriksson 1983; Kelly et al. 1984; Meulenaar et al.
1983; Sewelius 1986; Wilsdorf et al. 1985). The prevalence
was very high, ranging from 25 to 46% in different Bed-
lington terrier populations (Herrtage et al. 1987; Ubbink
et al. 2000).
Familial predisposition and an increased incidence of a
disease in a closed population, such as the Bedlington
terrier breed, indicate a hereditary etiology. Test matings
conﬁrmed this assumption and showed an autosomal
recessive inheritance pattern (Johnson et al. 1980; Owen
and Ludwig 1982). Selective breeding by excluding
affected dogs that were diagnosed based on a liver biopsy
led to a decrease in incidence of BTCT. In the well-doc-
umented Dutch Bedlington terrier population, the incidence
dropped dramatically from 46 to 11% (Ubbink et al. 2000).
However, because carrier dogs could not be identiﬁed by a
liver biopsy, there was a need for a DNA test for eradi-
cation of the disease.
A search for the causal gene was initiated by several
research groups, resulting in the exclusion of genes coding
for the copper transporter ATP7B (Dagenais et al. 1999;
van de Sluis et al. 1999), metal transporter ATP6H (Nanji
et al. 2001), copper transporters CTR1 and CTR2 (van de
Sluis et al. 1999) and the copper chaperone ATOX1
(Dagenais et al. 1999; Nanji and Cox 1999) as candidates
for BTCT based on mapping criteria or resequencing
efforts. The application of the ﬁrst whole-genome linkage
study with microsatellite markers in dogs led to the
detection of linkage between the microsatellite marker
C04107 and BTCT (Yuzbasiyan-Gurkan et al. 1997). Two
alleles were present in the Bedlington terrier population,
and allele 2 cosegregated with BTCT. The frequency of
the disease-associated allele was very high in the Euro-
pean, American, and Australian populations and varied
from 0.31 to 0.5 (Holmes et al. 1998; Lee et al. 2007;
Rothuizen et al. 1999; Yuzbasiyan-Gurkan et al. 1997).
Whereas implementation of the microsatellite marker test
in the breeding programs was an important step forward in
decreasing the disease incidence within the Bedlington
terrier populations, the search for the causal gene con-
tinued. A positional cloning strategy identiﬁed a large
genomic deletion of 39.7 kb encompassing exon 2 of the
originally named MURR1 gene (Forman et al. 2005; van
De Sluis et al. 2002). This MURR1 gene was previously
not known to be involved in copper metabolism, and
copper-binding motifs in the predicted protein product
were not recognized in this stage. Upon discovery of nine
other proteins related to the MURR1 protein, the gene was
renamed into Copper Metabolism gene MURR1 contain-
ing Domain 1 (COMMD1) (Burstein et al. 2005). All ten
proteins are characteristic for the COMM domain, which
seems to be necessary for the interaction among the
COMMD proteins as well as for the interaction with other
proteins (Burstein et al. 2005; Chang et al. 2011; de Bie
et al. 2007b; Drevillon et al. 2011; Maine et al. 2007;
Narindrasorasak et al. 2007; Thoms et al. 2010; van de
Sluis et al. 2007a, 2009).
Neither full-length nor truncated COMMD1 protein was
detectable in liver homogenates of affected Bedlington
terriers, suggesting that COMMD1 exon 2 deletion results
in a complete loss of function of COMMD1 (Klomp et al.
2003). In retrospect, the C04107 microsatellite marker was
positioned within the COMMD1 gene in intron 1, 13.5 kb
upstream of the exon 2 deletion (Forman et al. 2005).
Although in the majority of cases C04107 allele 2 was
linked to copper toxicosis, linkage of allele 1 to the disease
phenotype was reported as well (Haywood et al. 2001;
Holmes et al. 1998; Yuzbasiyan-Gurkan et al. 1997). In an
American Bedlington terrier pedigree, it was conﬁrmed
that C04107 allele 1 was linked to the exon 2 deletion,
implying that direct analysis for the exon 2 deletion would
be the only reliable genetic test for copper toxicosis in the
Bedlington (Favier et al. 2005; Lee et al. 2007; van de Sluis
et al. 2003). The presence of the new haplotype in the
American Bedlington terriers raised the question whether
this haplotype had a different genetic origin, or occurred
due to a recombination event between the microsatellite
marker and the exon 2 deletion (van de Sluis et al. 2003).
Remarkably, affected Bedlington terriers that were het-
erozygous for the exon 2 deletion or had two copies of the
normal exon 2 were identiﬁed in Finnish and Australian
populations. In these populations, a transition near the 50
splice site mutation of COMMD1 exon 2 was found.
However, no effect of this C-to-A transition on splicing
was noted by analysis of cDNA, and no association
between this mutation and BTCT could be established
(Coronado et al. 2003; Hyun et al. 2004). In these dogs,
another mutation may be responsible for the observed
disease phenotype.
In the search for modiﬁer genes of BTCT, the gene
coding for the copper transporter ATP7B was investigated
by DNA sequencing in a pedigree that did not show
complete cosegregation between the COMMD1 deletion
and BTCT. Eleven polymorphisms were identiﬁed, two of
which affected the encoded protein. One missense mutation
in exon 21 resulted in an amino acid change from arginine
to glutamine at a highly conserved position. However, all
investigated Bedlington terriers were homozygous for this
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pedigree could be established (Coronado et al. 2008).
In conclusion, careful evaluation of the copper toxicosis
phenotype in the Bedlington terrier and genetic mapping
studiesledtothediscoveryoftheCOMMD1gene,whichwas
previously unknown to be involved in copper metabolism.
This illustrates the relevance ofstudyingspontaneous disease
phenotypes to unravel important gene functions. The homo-
zygous state for the exon 2 deletion in COMMD1 causes
copper toxicosis in Bedlington terriers. Identiﬁcation of the
causal mutation led to an enormous decrease in the disease
frequency in Bedlington terrier populations and was very
beneﬁcial for the breed. However, the presence of one or two
normal copies of COMMD1 exon 2 does not exclude copper
toxicosis in subpopulations of Bedlington terriers. In these
dogs copper toxicosis may be explained by unidentiﬁed
mutations in regulatory elements of COMMD1 or in an
unidentiﬁed gene.
Molecular function of COMMD1
COMMD1 speciﬁcally binds Cu(II), for which the binding
site is located in the exon 2 product that is deleted in
affected Bedlington terriers (Narindrasorasak et al. 2007).
Direct biochemical evidence for involvement of COMMD1
in cellular copper metabolism was provided by the obser-
vation of copper accumulation after RNAi knockdown
of COMMD1 in canine, human, and murine cell lines
(Bursteinetal.2004;Miyayamaetal.2010;Speeetal.2007).
The deﬁcient copper excretion into the bile in the
Bedlington terrier (Su et al. 1982a) suggests a function for
COMMD1 in copper excretion. Affected Bedlington terri-
ers show massive copper accumulation in the hepatocytic
lysosomes, which, in combination with the observation that
COMMD1 localizes to a vesicular compartment, led to the
hypothesis that COMMD1 facilitates degranulation of the
lysosomal content into the bile (de Bie et al. 2005; Klomp
et al. 2003) (Fig. 1).
Interestingly, COMMD1 was found to interact with the
amino terminus of ATP7B (Lutsenko and Petris 2003;
Voskoboinik et al. 2002), suggesting that COMMD1 may
cooperate with ATP7B by facilitating copper transport
from the trans-Golgi network (TGN) to the canalicular
membrane of the hepatocytes for biliary excretion. As
ceruloplasmin levels in affected Bedlington terriers are
normal (Su et al. 1982b), copper transport to the Golgi
compartment seems to be unaltered. Copper-induced
translocation of ATP7B from the TGN to dispersed vesi-
cles was not impaired by depletion of COMMD1, which
indicates indeed that COMMD1 plays a role later in the
process of copper excretion (Weiss et al. 2008). Facilitation
of recruitment of ATP7B from the vesicles back to the
TGN in low-copper conditions may be another role of
COMMD1 in the regulation of efﬁcient copper efﬂux by
ATP7B (Miyayama et al. 2010).
In addition, COMMD1 was found to stabilize the
ATP7B protein and may be involved in its quality control
by promoting degradation of newly synthesized and
incorrectly folded ATP7B proteins (de Bie et al. 2007b).
Intriguingly, this interaction increased when ATP7B was
mutated, indicating that COMMD1 may contribute to the
molecular basis of WD.
Apart from its role in ATP7B functioning, COMMD1
has several other roles in copper homeostasis. It also binds
ATP7A, the homolog of ATP7B which is defective in
copper deﬁciency disorders in man (Kaler 2011). Interest-
ingly, binding of COMMD1 to mutant ATP7A partially
restored protein expression, subcellular localization, and
copper-exporting activities (Vonk et al. 2011).
Recently, it was discovered that COMMD1 can bind to
SOD1 and plays a role in the maturation and activation
of this protein (Fig. 1). RNAi-mediated knockdown of
COMMD1 expression resulted in a signiﬁcant induction
of SOD1 activity and a consequent decrease in superoxide
anion concentrations, whereas overexpression of COM-
MD1 exerts the opposite effect (Vonk et al. 2010).
As is shown above, COMMD1 has many functions in
the regulation of copper metabolism, but the regulation of
COMMD1 itself is not yet completely understood.
Intracellular trafﬁcking of many copper-binding proteins
is regulated by intracellular copper levels (van den Berghe
and Klomp 2010); however, this does not seem to be
the case for COMMD1, as subcellular localization of
COMMD1 is not inﬂuenced by intracellular copper levels
(Klomp et al. 2003).
Besides copper-dependent transcriptional regulation
(Muller et al. 2007), different forms of ubiquitination were
found to be important for COMMD1 regulation. XIAP
(Burstein et al. 2004; Maine et al. 2009), HSCARG (Lian
and Zheng 2009), Clusterin (Zoubeidi et al. 2010), and
ARF (Huang et al. 2008) were identiﬁed as COMMD1
interacting proteins regulating several components of this
process.
A physiological role for the interaction between
COMMD1 and XIAP was supported by the fact that
increased levels of XIAP expression induced copper accu-
mulation in several cell models, and XIAP deﬁciency in
mice led to decreased hepatic copper concentration
(Burstein et al. 2004). Interestingly, copper itself speciﬁ-
cally binds to the cysteine residues of the XIAP protein and
is delivered to XIAP via CCS (Brady et al. 2010) (Fig. 1).
The binding of copper results in a conformational change of
XIAP that induces an increased intracellular degradation
and impairs the ability to inhibit caspases, thus lowering the
apoptotic threshold (Mufti et al. 2006). This phenomenon
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hepatitis, which starts with copper accumulation followed
by hepatocellular apoptosis. Oxidative stress induced by
free copper may not be the only trigger, as has been the
general belief; this may have implications for therapeutic
interventions.
Ubiquitous expression of COMMD1 in a number of
different cell types indicates a more pleiotropic function of
COMMD1 than copper metabolism alone (Klomp et al.
2003). Indeed, COMMD1 was found to be involved in
many different cellular processes, including sodium
metabolism (Biasio et al. 2004; Chang et al. 2011; Ke et al.
2010), regulation of NFjB (Burstein et al. 2005; Maine and
Burstein 2007), and HIF1a-mediated transcription (van de
Sluis et al. 2007b, 2009, 2010).
Upon identiﬁcation of COMMD1 in the Bedlington
terrier, many new functions of COMMD1 were discovered
and more knowledge has been gained about the function
and regulation of this interesting protein. Although the
entire function of COMMD1 in copper homeostasis is not
completely resolved yet, recent data indicate that it at least
plays a role in the functioning and stability of ATP7B. This
may indicate that human Wilson’s disease and canine
COMMD1-deﬁcient copper toxicosis partly share their
disease mechanism through disturbance of ATP7B-medi-
ated copper export from hepatocytes.
COMMD1 in human copper toxicosis
The non-Wilsonian forms of copper toxicosis—ICC, ETIC,
and ICT—resemble the hepatic form of Wilson’s disease,
but in contrast there is no neurological involvement and the
age of onset is often early in childhood (Table 1). In these
diseases, consanguinity and high dietary copper intake are
suggested to play a role in the pathogenesis (Muller et al.
1996; Scheinberg and Sternlieb 1996; Tanner 1998). Since
a direct role of ATP7B mutations had been excluded and
the phenotype of humans with ICC, ETIC, or ICT resem-
bles that of BTCT, COMMD1 was tested as a candidate
gene. In two small studies of 23 and 3 cases, respectively,
no correlation between mutations and phenotype could be
established (Coronado et al. 2005; Muller et al. 2003).
In Wilson’s disease there is a wide variety of mutations in
ATP7B.Theclinicalpresentationinitshepaticorneurological
form is highly variable, even among patients with the same
mutation, which led several research groups to propose that
this variation may be subject to other modulating genes
(Riordan and Williams 2001;S c h a e f e re ta l .1999;T h o m a s
et al. 1995). As COMMD1 is known to interact with ATP7B
and both proteins work in conjunction copper excretion,
COMMD1 is an interesting candidate modiﬁer in patients
with Wilson’s disease with an atypical presentation or in
whomnooronlyonemutationwasdetected.Severalresearch
groups screened their WD patient cohorts for mutations in
COMMD1. Heterozygosity of a silent missense mutation
c.492GAT[GAC (Asp164Asp) in COMMD1wasreported
tobepossibly associatedwith anearlier onset ofneurological
manifestation of Wilson’s disease (Stuehler et al. 2004);
however,whereasthismutationwasobservedinothercohorts
as well, an association with the phenotype could not be con-
ﬁ r m e d( G u p t ae ta l .2010; Lovicu et al. 2006; Weiss et al.
2006). Several other mutations in COMMD1 were detected,
but none of them was signiﬁcantly correlated with variations
ofthediseasephenotype(Coronadoetal.2005;Hayashietal.
2007; Lovicu et al. 2006; Weiss et al. 2006;W ue ta l .2006).
Recently, a new mutation in COMMD1 was described in
a patient with Wilson’s disease. This nonsynonymous
change, c.521 ACG ? ATG; Thr174Met, resided in the
recently identiﬁed NES (Nuclear Export Signal) region.
The patient carrying this mutation was a compound het-
erozygote for WD mutations and exhibited extremely high
urinary copper levels. In this case, the COMMD1 mutation
may have contributed to exaggeration of the disease phe-
notype (Gupta et al. 2010).
Studies aiming to ﬁnd COMMD1 mutations to explain
the variability in WD are, in general, difﬁcult to perform
for two reasons. First, the disease is rare and therefore
recruitment of a large enough cohort is a challenge. Sec-
ondly, WD cohorts are heterogeneous with respect to
mutations in the ATP7B gene and the clinical presentation.
This makes it difﬁcult to establish a relationship between
variations in COMMD1 and clinical manifestation of WD.
In conclusion, although there are indications that
COMMD1 may be a modifying factor in human disorders
of copper metabolism, it does not seem to have a major
role. Thus far, unknown genes active in copper homeostasis
may be responsible for the observed disease phenotypes.
Copper storage diseases in dogs
In addition to copper toxicosis in the Bedlington terrier,
hereditary copper-associated liver disease has also been
described in other dog breeds such as the Dobermann
(Mandigers et al. 2004), the West Highland White terrier
(Thornburg et al. 1986), and the Dalmatian (Webb et al.
2002). More incidental reports of copper-storage-related
hepatitis are available for the Anatolian shepherd (Bosje
et al. 2003) and the Skye terrier (Haywood et al. 1988).
Recently, the Labrador retriever, which forms one of the
largest purebred dog populations worldwide, was docu-
mented to have an inherited form of copper-associated
hepatitis (Hoffmann et al. 2006). In addition, results from a
large survey of liver copper concentrations in dogs
(Thornburg et al. 1990) and results from a retrospective
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vaart et al. 2009) suggest that there may be more dog
breeds in which high liver copper levels and copper-asso-
ciated hepatitis are present.
Histologically, copper toxicosis in different dog breeds
shows many similarities. Accumulation of copper precedes
inﬂammatory changes in the liver and always starts in the
centrolobular regions of the liver lobules (zone 3). Around
the central vein branches, multifocal regions with increased
copper develop, ﬁrst in the hepatocytes which then become
apoptotic and are phagocytized, after which part of the
copper is concentrated in the Kupffer cells. The disease is
characterized by progressive inﬂammation, necrosis, and
bridging ﬁbrosis between centrolobular areas, eventually
leading to irreversible liver cirrhosis (Fig. 2). Cholestasis
can be present in very advanced stages of the disease but is
never the main histological ﬁnding. This is also under-
scored by blood tests which show that in copper toxicosis
the liver enzyme alanine-aminotransferase is often much
more increased than alkaline phosphatase, indicating
hepatocellular rather than cholestatic liver disease. Clinical
signs can result from acute severe liver failure or end-stage
cirrhosis and include lethargy, anorexia, vomiting, icterus,
ascites, and hepatoencephalopathy. In some breeds, acute
hemolytic crisis due to a massive release of copper into the
circulation is recognized. As in humans, treatment with the
copper chelators D-penicillamine and 2,3,2-tetramine is
effective in decreasing liver copper levels in dogs (Allen
et al. 1987; Hoffmann et al. 2009; Mandigers et al. 2005;
Twedt et al. 1988). Administration of zinc acetate or zinc
gluconate is described to have beneﬁcial effects in decop-
pering and in maintenance therapy (Brewer et al. 1992;
Hoffmann 2009; Hoffmann et al. 2009; Hoogenraad and
Rothuizen 1986).
Although there are many similarities in copper toxicosis
phenotypes between breeds, differences exist in clinical
Fig. 2 Histological appearance of copper-associated hepatitis in
different dog breeds. Slides are stained with rubeanic acid and
hematoxylin counterstain. a Liver biopsy of a female Bedlington
terrier clearly showing centrolobular distribution of copper. b Liver
biopsy of a female Bedlington terrier, 3 years of age with a liver
copper value of 11,500 lg/g dwl copper. Massive amounts of copper
granules are visible mainly in hepatocytes but also in Kupffer cells.
The central vein is located in the middle of the picture. c Liver biopsy
of a female Labrador, 5 years of age with a liver copper concentration
of 2,360 lg/g dwl. Copper granules are present in hepatocytes and
macrophages in the centrolobular area. The centrolobular region is
characterized by loss of hepatocytes, mild ﬁbrosis, and moderate
numbers of lymphocytes and plasma cells. d Liver biopsy of a female
Dobermann, 6 years of age with a liver copper value of 1,700 lg/g
dwl. The centrolobular area (bottom right of the picture) is
characterized by mild ﬁbrosis with multifocal accumulation of
macrophages containing lipofuscin pigment and copper granules.
Furthermore, this area shows moderate inﬁltration with lymphocytes.
Hepatocytes in the centrolobular region contain moderate amounts of
copper granules
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following subsections and summarized in Table 1.
Bedlington terrier
Although there are some reports of atypical copper toxi-
cosis in Bedlington terriers, a homozygous COMMD1 exon
2 deletion is causative for BTCT in the majority of dogs
(van De Sluis et al. 2002). Impaired biliary copper excre-
tion leads to a massive accumulation of copper in the liver,
which is the highest that is recognized in any dog breed.
Copper levels as high as 2,000 lg/g dwl are already rec-
ognized in 1 year old dogs; however, often no histological
signs of hepatitis are present then (Su et al. 1982b; Twedt
et al. 1979). Hepatitis develops around 2–5 years of age
and the dogs become clinically ill. Successful treatment is
possible with D-penicillamine. Without treatment, the
hepatic copper level tends to increase over time and can
reach values of 5,000 lg/g dwl. In some cases extremely
high liver copper levels of 15,000 lg/g dwl have been
reported. A tendency toward a decrease in liver copper
levels is present in old animals or in advanced stages of
liver cirrhosis (Twedt et al. 1979).
West Highland White terrier
Hepatitis associated with hepatic copper accumulation was
ﬁrst reported in this breed in the Unites States (Thornburg
et al. 1986). Later, the same authors reported on a larger
group of 71 dogs, of which many were related (Thornburg
et al. 1996). The disease had a clear familial distribution,
and when two affected dogs were mated, all dogs in the
offspring showed increased liver copper values, indicating
a hereditary background. Of the 71 cases investigated by
Thornburg et al., 44 had a highly increased copper con-
centration with an equal distribution over both sexes.
Copper levels do not reach the extremely high values seen
in the Bedlington terrier (the highest value reported was
6,800 lg/g dwl); however, the majority of affected West
Highland White terriers has copper concentrations around
2,000 lg/g dwl.
Dobermann
Dobermanns have been reported to have a very severe form
of hepatitis and cirrhosis, which is seen almost exclusively
in females and often has a fatal course within weeks or a
few months after diagnosis. Reports from the U.S.
(Thornburg 1998), Finland (Speeti et al. 1998), and the
Netherlands (Mandigers et al. 2004, 2007; Spee et al. 2005;
van den Ingh et al. 1988) describe increased copper con-
centrations and a predominant monocellular inﬁltrate in
the liver of affected Dobermanns. In the Dutch population,
a random sample of 15% of a cohort of 3-year-old
Dobermanns was followed over time. In 6% of these dogs,
copper-associated subclinical hepatitis was present and
liver copper levels increased to 1,000 lg/g dwl over time.
The etiologic role of copper was demonstrated by the
dramatic improvement upon treatment with D-penicilla-
mine and the associated normalization of copper concen-
trations (Mandigers et al. 2005). Mandigers et al. (2007)
also demonstrated that the biliary excretion of intrave-
nously injected
64Cu tends to be decreased in affected
Dobermanns.
MHC class II antigen expression was detected in hepa-
tocytes in cases of Dobermann hepatitis, but not in control
tissue (Speeti et al. 2003). Therefore, Dobermann hepatitis
was suggested to be an autoimmune disease. Induction of
MHC class II antigen expression in nonlymphatic cells can
also be induced by toxins, like copper. Homozygosity for
DLA-DRB1*00601 of the dog leukocyte antigen (DLA)
system genotype was found to be associated with an
increased risk for Dobermann hepatitis in Finnish Dober-
manns (Dyggve et al. 2011). Dobermann hepatitis behaves
quite differently compared with other copper storage dis-
eases with respect to the very severe prognosis when left
untreated, the strong female predisposition, and the rela-
tively mild increase in hepatic copper levels associated
with severe disease. Female predisposition is a common
feature for autoimmune diseases both in humans and in
dogs. Possibly, there is a combined role for copper accu-
mulation and autoimmune deregulation in the pathogenesis
of Dobermann hepatitis.
Currently, genome-wide association studies followed by
next-generation sequencing of associated regions and RNA
sequencing efforts are being performed in the combined
Dutch and Finnish cohorts of Dobermann hepatitis liver
samples within the LUPA initiative (Lequarre et al. 2011).
Dalmatian
One report from the U.S. (Webb et al. 2002) has con-
vincingly demonstrated that the Dalmatian has an inherited
copper storage disease causing hepatitis and liver cirrhosis.
Early case reports (Cooper et al. 1997; Noaker et al. 1999)
already had indicated the presence of a copper storage
disease in the American population. The mean hepatic
copper concentrations that were reported ranged from 650
to 9,424 lg/g dwl. In the liver biopsies, necroinﬂammatory
alterations were present in regions with copper-laden
hepatocytes and Kupffer cells. Several cases in the Neth-
erlands and Germany have been diagnosed (J. Rothuizen,
personal communication), so that this disease is also
present in European Dalmatians. However, currently reli-
able incidence estimates are lacking. There seems to be no
sex predisposition in this breed.
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An increased incidence of chronic hepatitis was reported in
the Labrador retriever previously (Andersson and Sevelius
1991). However, Hoffmann et al. (2006) were the ﬁrst to
demonstrate an association of increased liver copper levels
and hepatitis in this breed in Dutch Labrador retrievers.
Soon thereafter, copper-associated hepatitis in the Ameri-
can Labrador retriever population was recognized as well
(Shih et al. 2007; Smedley et al. 2009). There is a strong
female predisposition and breeding bitches in the post-
partum period have an increased risk for clinical illness.
Hormones or an increased stress on the liver during preg-
nancy and lactation may inﬂuence deterioration of the liver
function; however, no evidence for this hypothesis cur-
rently exists. Copper-accumulating traits in the Labrador
retriever show a heritability of up to 85% (Hoffmann et al.
2008). Involvement of environmental factors in the disease
pathogenesis was proven by the fact that dietary manage-
ment with a low-copper diet was effective in preventing
progression of the disease (Hoffmann et al. 2009). Unpub-
lished results demonstrated that the disease is polygenic and
the Labrador form of copper storage disease might become
a good example of the power of canine populations to
resolve complex genetic diseases (J. Rothuizen, personal
communication).
Opportunities and pitfalls in genetic studies into canine
copper storage disorders
Discovery of the COMMD1 gene in the Bedlington terrier
was an enormous step forward in the diagnosis of affected
and carrier dogs by use of a DNA test. The implementation
of this test in the selection of breeding dogs led to dramatic
decrease in the number of affected puppies that were born.
In addition, the subsequent functional studies have shed
a new light on the regulation of mammalian copper
metabolism.
However, several questions remain unanswered. A
minority of Bedlington terriers is affected with copper
toxicosis but do not have the homozygous COMMD1 exon
2 deletion. In addition, the role of COMMD1 as a modiﬁer
gene in Wilson’s disease was not clearly established, and
no causal mutations for non-Wilsonian forms of copper
toxicosis have been detected thus far. These phenomena are
a reﬂection of the complex regulation of copper metabo-
lism and it is likely that other as yet unidentiﬁed genes may
be at play.
In the preceding subsections we summarized the forms
of copper accumulation that are well documented in dif-
ferent dog breeds. The phenotypes in the dogs have some
resemblance with those of human copper storage disorders.
For example, copper accumulation in the liver and response
to D-penicillamine therapy are features that are both shared
among all human and canine forms of copper toxicosis.
The age of onset of the clinical signs in dogs is comparable
with the general age of onset of Wilson’s disease, i.e.,
adolescence or middle age.
In non-Wilsonian forms of copper toxicosis, a strong
inﬂuence of dietary copper intake on the expression of the
disease phenotype is noticed; the same strong effect is seen
in Labrador retrievers. On the other hand, a change to a
low-copper diet did not halt disease progression in Bed-
lington terriers (R. Favier, personal communication).
In dogs, no neurological impairments have been noticed,
although behavioral changes have been seen in Dober-
manns, Labradors, and Bedlington terriers. More research
is needed in order to conclude if copper accumulation in
the brain may inﬂuence these behavioral changes.
In the search for new genes involved in copper metab-
olism, genome-wide association studies in dog breeds with
a high prevalence of copper toxicosis could make a valu-
able contribution. Unlike the heterogeneity of most human
populations, the structure of dog breed populations is
homogeneous, which is advantageous for unraveling the
molecular genetics of complex diseases (Karlsson and
Lindblad-Toh 2008; Wilbe et al. 2010). For this reason, the
dog was one of the ﬁrst mammals whose genome was
sequenced to a high-quality level (Lindblad-Toh et al.
2005). As a consequence of breeding practices and popu-
lation bottlenecks, linkage disequilibrium (LD) in the dog
genome extends over distances that are up to 100 times
longer than in the human genome and the number of
haplotype variants in a breed is small (Lindblad-Toh et al.
2005; Sutter et al. 2004). This means that relative to human
studies, genotyping of a limited number of SNPs in small
patient and control groups sufﬁces for a genome-wide
association study. For this purpose, a 170K SNP array has
been developed by Illumina (San Diego, CA, USA) in
collaboration with the LUPA consortium (Lequarre et al.
2011). Large LD blocks in dogs may be a drawback in
pinpointing the location of the gene of interest; however,
ﬁne mapping across breeds is one way to overcome this
problem (Karlsson et al. 2007).
In addition to genetic homogeneity, the copper toxicosis
phenotype within breeds is also much more homogeneous
compared to, for example, WD phenotypes, which make a
correct diagnosis more feasible. No biomarkers for copper
status exist in dogs; therefore, a liver biopsy is always
needed to establish the diagnosis of copper toxicosis. This
is beneﬁcial for genetic studies because a precise copper
quantiﬁcation as well as a careful histological description
of the liver biopsy is often available. In addition, the
availability of liver tissue opens the opportunity for trans-
criptomics and proteomics studies in order to gain insight
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tions. Another important factor that can be controlled for in
dog populations is dietary copper intake. Most privately
kept dogs are fed a kibble diet in which copper concen-
trations are relatively stable and copper intake can be
estimated more precisely than in humans.
There are some pitfalls when applying genome-wide
association studies in canine copper toxicosis and they
have to be taken into account in study design and data
analysis. As stressed before, correct phenotyping is of
utmost importance in the design of a genetic study. Phe-
nocopies can occur as a result of liver copper accumulation
due to reduced bile ﬂow and this has to be distinguished
from primary copper accumulation resulting from a genetic
defect. In primary forms of copper accumulation, copper is
localized around the central veins in the liver lobule,
whereas copper accumulation due to cholestasis is present
in hepatocytes in the periportal areas. In advanced stages of
copper toxicosis, when liver cirrhosis is present, the
architecture of the liver is disturbed and localization of
copper within the liver lobe becomes a challenge. Also, in
advanced, untreated cases, liver copper levels may actually
decrease due to replacement of hepatocytes with ﬁbrotic
tissue and regenerative nodules that have not yet accumu-
lated copper. In these cases, it may become difﬁcult to
distinguish between chronic hepatitis due to primary cop-
per toxicosis and idiopathic chronic hepatitis. In conclu-
sion, for correct phenotyping an experienced veterinary
pathologist and a reliable method for quantitative copper
determination are indispensable.
In the data analysis of a genome-wide association study,
it is important to look for population substructuring and
encrypted relatedness in the dog sample as this can cause
false positive association signals. The use of mixed models
in the data analyses, for example, as implemented in the
software GenABEL (Aulchenko et al. 2007), can elegantly
correct for underlying population or family structure. In
addition, the use of this kind of model has the advantage
that traits, e.g., liver copper level, can be analyzed quan-
titatively and that modifying factors such as age of onset,
sex, and dietary copper intake can be implemented in the
analysis.
There is a high level of conservation of copper metab-
olism genes over species; therefore, it is likely that genetic
studies into canine copper toxicosis will contribute to an
increased knowledge into mammalian copper metabolism
and human copper storage diseases. It is clear that upon
identiﬁcation of new copper metabolism-associated genes
in purebred dog populations, the translational step to
human disease phenotypes needs to be made. Functional
studies to test the implications of mutations are indis-
pensable and cohorts of human patients will need to be
tested for involvement of the new genes. Therefore, a good
collaboration between canine and human research groups is
of utmost importance.
Concluding remarks
The discovery of the COMMD1 gene through genetic
studies in Bedlington terrier copper toxicosis has led to a
great increase in knowledge about the regulation of mam-
malian copper metabolism. However, several questions
with respect to the etiology of copper toxicosis in both man
and dogs remain to be answered. The treasury of purebred
dog populations for genetic studies is expected to reveal
many new details of copper homeostasis in the coming
years and will be beneﬁcial to both man and dog.
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